Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2026
Reporting Period: Second Quarter ended June 30, 2026
This filing announces the release of the Company's results of operations and financial condition for the second quarter of 2026. The report incorporates by reference a press release (Exhibit 99.1), an updated corporate investor presentation (Exhibit 99.2), and an earnings call presentation (Exhibit 99.3).
Key Financial Metrics
The provided text serves as a cover document for the release of financial results and does not contain specific numerical data. Consequently, the following metrics are not available in this filing text:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Material Changes
The filing text does not detail specific material changes in financial performance or operational status compared to prior periods. It only confirms the issuance of the Q2 2026 results and related presentations.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes a standard caution regarding forward-looking statements. These statements relate to anticipated performance under the "Tempus Agreement" and the "Restated Agreement," as well as other non-historical facts.
Risks and Uncertainties: Management notes that actual results may differ materially from projections due to known or unknown risks. Investors are directed to the "Risk Factors" section of the Company's most recent Form 10-K and subsequent Form 10-Q filings for a detailed description of these risks.
Legal Disclaimer: Information furnished under Items 2.02 and 7.01, including the exhibits, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly incorporated by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 and 99.3 for updated corporate strategy and pipeline progress.
- Verify the status and performance metrics related to the Tempus Agreement and Restated Agreement mentioned in the forward-looking statements.
- Consult the most recent Form 10-K and Form 10-Q for detailed risk factors not summarized in this 8-K.